Sponsor Dossier
Eisai
Sponsor Dossier for Eisai. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ARX-LENVATINIB
- Brand: DAYVIGO
- Brand: FYCOMPA
- Brand: HALAVEN
- Brand: INOVELON
- Brand: LENVIMA
- Brand: LEQEMBI
About
Eisai is an Australian Private Company with ABN 73117970993, registered in Victoria. The company is currently active.
Portfolio
Eisai has seven brands on the ARTG, with six indexable brands and six brands with Product Information on file. Four brands have PBAC outcomes on record and four brands have AusPARs on record. No brands are currently PBS-listed. Notable brands include ARX-LENVATINIB, DAYVIGO, FYCOMPA, HALAVEN, INOVELON, LENVIMA, and LEQEMBI.
Therapeutic focus
— Neurology: 4 brands — Oncology: 3 brands
Regulatory activity
Eisai's latest PBAC outcome is dated 1 July 2024, with four brands holding PBAC outcomes on record. The latest AusPAR on file is dated 11 February 2021, with four brands holding AusPARs on record.